Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib plus salvage chemotherapy vs chemotherapy alone in relapsed/refractory FLT3-mutated AML
2017-001600-29Phase 3Active
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Crenolanib arm with Placebo arm (2 arms). Primary endpoint: Event-free survival. Started Apr 2018; status: active.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-001600-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001600-29.